 |
 |

Treating Imagined Ugliness
Arch Gen Psychiatry. 1999;56:1041-1042.
 |
 |
| Since this article does not have an abstract, we have provided the first 150 words of the full text and any section headings. |
|
 |
 |
BODY dysmorphic disorder (BDD) is an intriguing and relatively common1-2 syndrome that can challenge the clinical acumen of the most seasoned clinician. In the psychiatric literature, patients with BDD are described as extremely difficult to treat,3 and a noted dermatologist has stated, "The author knows of no more difficult patients to treat than those with body dysmorphic disorder."4(p463)
The DSM-IV defines BDD as a distressing and/or impairing preoccupation with a nonexistent or slight defect in appearance. The disorder can cause severe distress and markedly impaired functioning.5-9 A high percentage of patients require hospitalization, become housebound, and attempt suicide.9-10 Despite their suffering, patients are often secretive about their symptoms, and the disorder usually goes unrecognized in clinical settings.2, 11
In this issue of the ARCHIVES, Hollander and colleagues12 have published the first controlled treatment trial of this serious and understudied disorder. Since BDD was first described more than a century ago,5 . . . [Full Text of this Article]
RELATED ARTICLE
Clomipramine vs Desipramine Crossover Trial in Body Dysmorphic Disorder: Selective Efficacy of a Serotonin Reuptake Inhibitor in Imagined Ugliness
Eric Hollander, Andrea Allen, Jee Kwon, Bonnie Aronowitz, James Schmeidler, Cheryl Wong, and Daphne Simeon
Arch Gen Psychiatry. 1999;56(11):1033-1039.
ABSTRACT
| FULL TEXT
THIS ARTICLE HAS BEEN CITED BY OTHER ARTICLES
 |
Fluoxetine was safe and effective for body dysmorphic disorder
Rao
Evid. Based Ment. Health 2002;5:119-119.
FULL TEXT
|